Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM
Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet...
Cancer
KFSHRC Leads Healthcare Intelligence in Diagnostics and Patient Care
RIYADH, Saudi Arabia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is contributing to...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence,...
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an...
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of...
Enable Me Reminds Women of the Importance of Regular Breast Screenings on National Mammogram Day Tomorrow
To aid in the early detection of breast cancer, Enable Me is offering Tampa Bay area mammography clinics free use...
Breakthrough Properties Joined by San Diego Mayor Todd Gloria to Celebrate the Opening of Torrey View By Breakthrough Development
Fully Leased Life Science Campus is Now Home to Leading Companies Including Pfizer and BD Biosciences SAN DIEGO, Oct. 17,...
Cancer: Crosetto’s Breakthrough Inventions with Potential to Save Millions of Lives and Billions of Dollars Approved for a Two-Hour Presentation at IEEE
DALLAS, Oct. 17, 2024 /PRNewswire/ -- Crosetto Foundation for the Reduction of Cancer Deaths welcomes Transparency in Science. Italian-American scientist...
Evvy Announces the Company’s First Chief Medical Officer and Publishes Peer-Reviewed Validation on the Evvy Vaginal Health Test, Advancing its Mission of Unlocking Precision Female Healthcare
Evvy Names Dr. Kate McLean, MD, MPH, FACOG as Chief Medical Officer, publishes peer-reviewed validation paper for its at-home vaginal...
Biodexa’s MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survivalCARDIFF, UK...
Biodexa’s MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survivalCARDIFF, UK...
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage...
Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate
-- BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development -- -- Phase 1/2a study will evaluate BPT567...
ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for...
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience...
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)
First payment received under Tonix’s contract with the Defense Threat Reduction Agency (DTRA), for up to $34 million over five...
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
Media Release First safety data anticipated before year end with assessment of PK/PD relationships to follow in H1’CY2025 SYDNEY, AUSTRALIA,...
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare...
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG...